Brady Todd C 4

What Happened Brady Todd C, President, CEO and a director of Aldeyra Therapeutics (ALDX), acquired 250,000 shares in an open-market purchase (transaction code P) on June 3, 2026. The reported weighted-average price was $1.67 per share, for a total purchase value of approximately $418,450. This was a purchase (insider buying), which some investors view as a more informative signal than routine selling, although no motive can be inferred from the filing.

Key Details

• Transaction date: 2026-06-03 (reported on Form 4 filed 2026-06-05). Filing appears timely (Form 4 is generally due within two business days).
• Price: weighted average $1.67; footnote indicates individual trades ranged from $1.64 to $1.70.
• Shares acquired: 250,000 (total value ≈ $418,450).
• Shares owned after transaction: not provided in the excerpt supplied.
• Footnote: filer notes the $1.67 is a weighted average and can provide the per-trade breakdown (prices $1.64–$1.70) to the issuer or SEC staff upon request.
• Transaction type: P = Purchase (open-market).

Context This was an open-market purchase by the company's CEO — a straightforward cash buy rather than an option exercise, gift, or award. Purchases by executives are often watched by retail investors as one data point on insider confidence, but they do not alone prove future company performance.